Invitrogen obtains patents to sell Affymetrix's microarrays

By Lisa Kerner

Charlotte, N.C., June 21 - Invitrogen Corp. said it has obtained a non-exclusive, worldwide license to a number of Affymetrix Inc. patents, allowing it to manufacture and sell spotted nucleic acid microarrays in the research field.

Financial details of the agreement were not disclosed, according to a company news release.

Santa Clara, Calif.-based Affymetrix develops, manufactures and sells systems for genetic analysis, including its GeneChip technology.

Invitrogen, located in Carlsbad, Calif., provides life science technologies for disease research, drug discovery and commercial bioproduction.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.